Fexapotide for BPH
Ronald F. Tutrone, Jr., MD, FACS, summarizes two Phase III clinical trials testing the safety and efficacy of fexapotide, a novel treatment for benign prostatic hyperplasia (BPH).
Read More
Featured Content
Localized Upper Tract Urothelial Carcinoma Managed with “Watchful Waiting”
Peter Schulam MD, PhD, compares and contrasts the Surveillance, Epidemiology, and End Results (SEER) database and the National Cancer Database (NCDB) in terms of reliability for assessing upper tract urothelial carcinoma (UTUC) outcomes and risk factors when determining whether to treat a patient with definitive therapy or the “Watchful Waiting” strategy.
Read More
Multimodal Approach to Advanced Prostate Cancer
Martin E. Gleave, MD, FRCSC, FACS, discusses his views on improving advanced prostate cancer treatment approaches. Specifically, he emphasizes methods that integrate various treatment options beyond surgical castration and androgen deprivation therapy (ADT).
Read More SpaceOAR Hydrogel – Prostate-Rectum Spacing in Radiation Therapy
Lawrence I. Karsh, MD, FACS, discusses the use of SpaceOAR Hydrogel to reduce risk of rectal complications and improve quality of life (QOL) outcomes when treating prostate cancer with radiation therapy. He summarizes supporting clinical evidence, describes the physical application of the gel, and lists players currently offering coverage for the procedure.
Read More M0 Space and The SPARTAN Trial
Eric J. Small, MD, defines nonmetastatic castration-resistant prostate cancer, or M0 disease. He then discusses the design, implementation, and results of the SPARTAN trial, which he presented at the 2018 Genitourinary Cancers Symposium. The study tested the efficacy of apalutamide in men with M0 disease.
Read More